EntryPoint Capital LLC Takes $308,000 Position in Ocular Therapeutix, Inc. $OCUL

Key Points

• EntryPoint Capital LLC acquired a new stake in Ocular Therapeutix, purchasing 42,031 shares valued at approximately $308,000 in the first quarter of the year.
• Ocular Therapeutix reported a quarterly revenue of $13.46 million but had a loss per share (EPS) of ($0.39), missing analyst estimates by $0.04.
• Analysts maintain a consensus rating of "Buy" for Ocular Therapeutix, with a target price ranging from $15.00 to $20.00, indicating expectations of growth for the stock.

EntryPoint Capital LLC bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 42,031 shares of the biopharmaceutical company's stock, valued at approximately $308,000.

A number of other hedge funds have also bought and sold shares of OCUL. GF Fund Management CO. LTD. bought a new stake in Ocular Therapeutix in the fourth quarter valued at $28,000. Brooklyn Investment Group increased its stake in Ocular Therapeutix by 151.5% in the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 3,155 shares in the last quarter. GAMMA Investing LLC increased its stake in Ocular Therapeutix by 6,760.0% in the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 8,112 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 8,446 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Ocular Therapeutix in the first quarter valued at $79,000. Institutional investors own 59.21% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Scotiabank decreased their price target on shares of Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating for the company in a research note on Wednesday, August 6th. Needham & Company LLC lifted their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $17.20.

Ocular Therapeutix Stock Down 3.5%

OCUL stock traded down $0.43 during trading on Monday, reaching $11.87. The stock had a trading volume of 903,074 shares, compared to its average volume of 1,792,738. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $12.91. The company has a quick ratio of 10.02, a current ratio of 10.10 and a debt-to-equity ratio of 0.23. The company's 50 day moving average is $10.91 and its two-hundred day moving average is $8.70. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -9.27 and a beta of 1.49.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The firm had revenue of $13.46 million during the quarter, compared to the consensus estimate of $13.12 million. During the same period in the previous year, the company posted ($0.26) earnings per share. The company's revenue for the quarter was down 17.7% on a year-over-year basis. Equities research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.